

- circulating fetal cells. *Lancet*. 2003;361(9362):1013–1014.
- Betz CL, Linroth R, Butler C, et al. Spina bifida: what we learned from consumers. *Pediatr Clin North Am*. 2010;57(4):935–944.
- Boitano LJ. Equipment options for cough augmentation, ventilation, and noninvasive interfaces in neuromuscular respiratory management. *Pediatrics*. 2009;123(Suppl 4):S226–S230.
- Bosanquet M, Copeland L, Ware R, et al. A systematic review of tests to predict cerebral palsy in young children. *Dev Med Child Neurol*. 2013;55(5):418–426.
- Bush A, Fraser J, Jardine E, et al. Respiratory management of the infant with type 1 spinal muscular atrophy. *Arch Dis Child*. 2005;90(7):709–711.
- Centers for Disease Control and Prevention. *Botulism: general information: frequently asked questions*. <http://www.cdc.gov/nczved/divisions/dfbmd/diseases/botu> 2010.
- Centers for Disease Control and Prevention. *Data and statistics for cerebral palsy: prevalence and characteristics*. <http://www.cdc.gov/NCBDDD/cp/data.html>; 2013.
- Centers for Disease Control and Prevention. Folate status in women of childbearing age, by race/ethnicity—United States, 1999–2000, 2001–2002, and 2003–2004. *MMWR Morb Mortal Wkly Rep*. 2007;55(51–52):1377–1380.
- Centers for Disease Control and Prevention. Racial/ethnic differences in the birth prevalence of spina bifida—United States, 1995–2005. *MMWR Morb Mortal Wkly Rep*. 2009;57(53):1409–1413.
- Centers for Disease Control and Prevention. Updated recommendation for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(01):13–15.
- Dai AI, Wasay M, Awan S. Botulinum toxin type A with oral baclofen versus oral tizanidine: a randomized pilot comparison in patients with cerebral palsy and equines foot deformity. *J Child Neurol*. 2008;23(12):1464–1466.
- Dicianno BE, Fairman AD, Juengst SB, et al. Using the spina